Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Quadruplet Regimens Seek to Raise the Bar in Frontline Multiple Myeloma

October 12th 2020

Derek Galligan, MD, discusses the role of 3-drug combinations and ongoing research efforts that are focused on evaluating the use of quadruplet regimens earlier on in the treatment journey.

Dr. Vesole on Developing Off-the-Shelf CAR T-Cell Therapy in Multiple Myeloma

October 9th 2020

David H. Vesole, MD, PhD, discusses the importance of developing off-the-shelf CAR T-cell therapy products in multiple myeloma.

Dr. Lonial Discusses Ongoing Research With BiTEs and CAR T-Cell Therapy in Myeloma

October 6th 2020

Sagar Lonial, MD, FACP, discusses the development of bispecific T-cell engagers (BiTEs) and CAR T-cell therapy in multiple myeloma.

Dr. Vesole on the Advantages of CAR T-Cell Therapy in Multiple Myeloma

October 5th 2020

David H. Vesole, MD, PhD, discusses the advantages of CAR T-cell therapy in multiple myeloma.

Dr. Silberman on Treatment Options in Early-Relapse Multiple Myeloma

October 2nd 2020

Rebecca Silbermann, MD, MMS, discusses current treatment options for fit patients with multiple myeloma who experience early relapse.

Belantamab Mafodotin in Relapsed/Refractory Myeloma Requires Multidisciplinary Effort

October 1st 2020

Sanjay V. Patel, MD, FRCOphth, discusses the corneal-associated toxicities that can occur with belantamab mafodotin and the need for multidisciplinary management to optimally administer this agent.

Experts Examine Predictive Value of MRD, Maintenance Strategies in Myeloma

September 30th 2020

Nina Shah, MD, and Sandy Wong, MD, discuss the predictive value of minimal residual disease and a potential course of treatment for a patient with revised International Staging System I multiple myeloma.

Monoclonal Antibodies, ADCs, and CAR T Cells Invigorate the Myeloma Paradigm

September 29th 2020

David H. Vesole, MD, PhD, discusses the evolution of multiple myeloma treatment, and explained how other BCMA-therapies are poised to impact clinical practice.

From the Ophthalmologist’s Eye: Managing Ocular Toxicities With Belantamab Mafodotin in Myeloma

September 25th 2020

Shaily Shah, MD, discusses disease and treatment-related ocular toxicities that can arise in patients with cancer, specific management strategies for patients receiving belantamab mafodotin who develop ocular toxicities, and the importance of collaborative management of these patients.

BCMA-Targeted Approaches Revolutionize Relapsed/Refractory Myeloma Treatment

September 24th 2020

Elisabet E. Manasanch, MD, discusses novel BCMA-targeted modalities that are emerging in relapsed/refractory multiple myeloma.

Novel Combos With Belantamab Mafodotin May Move the Needle in Myeloma

September 24th 2020

Sagar Lonial, MD, FACP, discusses the approval of belantamab mafodotin-blmf and how it addressed an unmet need in relapsed/refractory multiple myeloma.

Triplet Regimens Dominate the Relapsed/Refractory Myeloma Treatment Landscape

September 22nd 2020

Kelly Godby, MD, discusses novel triplet combinations and how they are leading the key developments made in the treatment of patients with relapsed/refractory multiple myeloma in recent years.

FDA Grants Priority Review to Idecabtagene Vicleucel for Multiple Myeloma

September 22nd 2020

The FDA has granted a priority review designation to a biologics license application for idecabtagene vicleucel for the treatment of adult patients with multiple myeloma who have received at least 3 previous therapies.

Quadruplets Poised to Become New Standard in Frontline Transplant-Eligible Myeloma

September 17th 2020

Susan Bal, MD, discusses key trials in the multiple myeloma space.

Novel Agents Rouse Responses in Relapsed/Refractory Multiple Myeloma

September 16th 2020

Thomas G. Martin, MD, discusses the importance of targeted therapy in multiple myeloma, in addition to ongoing research.

Improved Induction Therapies Could Eliminate the Need for Transplant in Myeloma

September 16th 2020

Jeffrey Wolf, MD, discusses how induction therapies continue to improve the depth of response in patients with multiple myeloma and how it may be possible to eliminate the need for autologous stem cell transplant in this population.

Novel Triplet Combos Offer Deep Remissions in Relapsed/Refractory Multiple Myeloma

September 16th 2020

Joshua Richter, MD, discusses the importance of optimizing these novel therapies to make way for precision medicine in multiple myeloma.

Dr. Costa on the Promising Role of CAR T-Cell Therapy in Multiple Myeloma

September 14th 2020

Luciano J. Costa, MD, PhD, discusses the promising role of CAR T-cell therapy in relapsed/refractory multiple myeloma.

Dr. Arora on the Evolving Treatment Landscape in Multiple Myeloma

September 11th 2020

Shagun Arora, MD, discusses the rapidly advancing multiple myeloma treatment landscape.

Ixazomib Triplet Fails to Meet Primary End Point of PFS in Myeloma, Despite Improvement

September 11th 2020

Although the addition of ixazomib to lenalidomide and dexamethasone showed an improvement in progression-free survival in patients with newly diagnosed multiple myeloma who are not candidates for autologous stem cell transplant, it was not determined to be of statistical significance.